Please amend claim 2 as follows:

2. A [pharmaceutical] composition for inducing apoptosis and inhibiting cell growth comprising the adenoviral vector of claim 1, (a vector encoding a protein that induces the expression of Bax gene encoded by the vector of claim 1) and [a pharmaceutically] an acceptable carrier.

A2

Please amend claim 3 as follows:

3. A method of treating an individual having a neoplastic disease [pathophysiological state], comprising the step of administering to said individual [a pharmacologically effective dose] an amount of the composition of claim 2 effective to inhibit neoplastic growth.

A3

Please amend claim 5 as follows:

5. The method of claim [4] 3, wherein said neoplastic disease is selected from the group consisting of breast cancer, colon cancer, ovarian cancer, glioma, osteosarcoma and haemopoietic cancers.

A4

Please amend claim 6 as follows:

A5

6. The method of claim [4] 3, wherein said composition is administered in a dose of from about 0.1 mg/kg to about 100 mg/kg.

Please amend claim 7 as follows:

Sub A2

A6

7. A method of treating an individual having ovarian cancer, comprising the step of administering to said individual [a pharmacologically effective dose of a pharmaceutical composition, comprising a recombinant adenoviral vector encoding an pro-apoptotic *bax* gene and a pharmaceutically acceptable carrier] an amount of the composition of claim 2 effective to inhibit ovarian cancer growth.

Please amend claim 9 as follows:

Sub A3

A7

9. A method of sensitizing tumor cells to chemotherapy and/or radiotherapy in an individual, comprising the step of administering to said individual [a pharmacologically effective dose of a pharmaceutical composition, comprising a recombinant adenoviral vector encoding an pro-apoptotic *bax* gene and a pharmaceutically acceptable carrier] an amount of the composition of claim 2 effective to sensitize said tumor cells.